Breast cancer risk is strongly associated with an intergenic region on 11q13. We have previously shown that the strongest risk-associated SNPs fall within a distal enhancer that regulates CCND1. Here, we report that, in addition to regulating CCND1, this enhancer regulates two estrogen-regulated long noncoding RNAs, CUPID1 and CUPID2. We provide evidence that the risk-associated SNPs are associated with reduced chromatin looping between the enhancer and the CUPID1 and CUPID2 bidirectional promoter. We further show that CUPID1 and CUPID2 are predominantly expressed in hormone-receptor-positive breast tumors and play a role in modulating pathway choice for the repair of double-strand breaks. These data reveal a mechanism for the involvement of this region in breast cancer.
Introduction
Genome-wide association studies (GWASs) provide an excellent means of identifying single-nucleotide polymorphisms (SNPs) that are associated with breast cancer (MIM: 114480) risk. 1, 2 Because the majority of identified SNPs fall outside of protein-coding regions, 3 a major challenge is determining how genetic variation in these regions contributes to disease. Several studies have shown that GWAS SNPs are enriched in regulatory regions and can influence the expression of nearby protein-coding genes. [3] [4] [5] [6] However, the contribution of noncoding RNAs to disease risk is still relatively unexplored, partly because noncoding RNAs are poorly annotated.
One of the strongest associations with breast cancer risk involves rs614367, located in an intergenic region at 11q13. 7 This association is restricted to risk of estrogenreceptor-positive (ER þ ) tumors. We previously fine-mapped this locus and found that the strongest genetic signal contained four SNPs located within a distal transcriptional enhancer (called PRE1) of CCND1 (MIM: 168461). 4 Here, we have identified two long noncoding RNAs (lncRNAs) transcribed from this region and name them CUPID1 and CUPID2 (CCND1-upstream intergenic DNA repair 1 and 2). We have found that PRE1 acts as a strong enhancer on the bidirectional promoter of CUPID1 and CUPID2.
Cell Fractionation
MCF7 cells were fractionated as previously described. 8 Real-Time qPCR cDNA was synthesized with SuperScript III (Invitrogen). qPCR was performed with Taqman assays (Life Technologies) or intron-spanning primers for determining gene expression (Table S1 ).
RNA CaptureSeq
RNA CaptureSeq was performed on MCF7 cells with and without estrogen stimulation and on five breast cell lines: HMEC, T47D, BT474, Hs578T, and MDAMB231. Oligonucleotide probes were designed to capture a 390 kb intergenic region on 11q13 (chr11: 69,064,954-69,455,655) as part of a larger study with the Roche NimbleGen Sequence Capture design algorithm. Locations of the capture probes are provided in Table S2 . Sequencing libraries were prepared and capture hybridizations was performed as previously described. 9 De novo transcripts were assembled as previously described. 9, 10 Chromatin Conformation Capture Chromatin conformation capture (3C) libraries were generated with NcoI or EcoRI as described previously. 5 3C interactions were quantitated by qPCR using primers designed within restriction fragments (Table S1 ).
Luciferase Assays
Promoter-driven reporter constructs were generated via the insertion of a CUPID1 or CUPID2 promoter sequence (chr11: 69,294,069-69,296,583) into the KpnI-XhoI sites of pGL3-Basic in the 5 0 /3 0 (CUPID1) or 3 0 /5 0 (CUPID2) direction ( Figure S1 ). A 3,334 bp fragment (chr11: 69,329,695-69,333,028) containing PRE1 with or without the risk SNPs was then inserted into the BamHI-SalI site of promoter-driven reporter constructs. Primers used for generating the promoter constructs are listed in Table S1 . Luciferase assays were performed as described previously. 5
CUPID1 and CUPID2 Overexpression
Sequences corresponding to the main isoforms of CUPID1 and CUPID2 ( Figure S2 ) were synthesized by GenScript and inserted into the Nhe1-Not1 or NheI-BamHI sites of pCDNA3.1. For reestablishment of CUPID1 and CUPID2 expression, the following procedures were employed: (1) For the formation of RAD51 foci, MCF7 CUPID1-and CUPID2-CRISPRi (CRISPR interference) cells were transfected with 2 mg of CUPID1 or CUPID2 expression plasmids, respectively, with the Nucleofector Kit V (Amaxa). (2) For the HR assay, MCF7 DR-GFP cells were co-transfected with I-SceI and 2 mg of CUPID1 or CUPID2 expression plasmids with Lipofectamine 3000 (Invitrogen).
siRNA Silencing
Two independent small interfering RNAs (siRNAs) were designed against CUPID1 or CUPID2 with the Dharmacon siDesign tool. A pool of three siRNAs was used against RAD51. The sequences are listed in Table S1 . 10 nM of siRNA was transfected into MCF7 cells with RNAiMax (Invitrogen), and cells were harvested 48 hr later.
CRISPRi
Single-guide RNA (sgRNA) sequences targeting the 11q13 PRE1 promoter or CUPID1 and CUPID2 promoter are provided in Table S1 . The sgRNA target, Cas9 binding handle, and terminator sequences were synthesized (Integrated DNA Technologies) and cloned into the lentiviral vector pgRNA-humanized. Virus-like particles (VLPs) containing either dCas9-KRAB or a targeting sgRNA were generated by transfection of HEK293 cells with Lipofectamine 2000 (Thermo Fisher Scientific). Cells were cotransfected with the packaging plasmid pCMV-dR8.91, the VSV-G expression plasmid pCMV-VSV-G, 11 and either pHR-SFFV-dCas9-BFP-KRAB or pgRNA-humanized. VLPs were collected, mixed in equal volume, and used for transducing MCF7 DR-GFP cells. Cells expressing mCherry (pgRNA) and blue fluorescent protein (dCas9-KRAB) were sorted by fluorescence-activated cell sorting (FACS) on an ARIA IIIu (Becton Dickinson).
RNA-Seq
RNA sequencing (RNA-seq) was performed on three independent replicates for each siRNA (nontargeting control, CUPID1, or CUPID2). Total RNA was extracted with TRIzol 48 hr after transfection with siRNAs, and 1 mg was depleted of ribosomal RNA (rRNA) with an Illumina Ribo-Zero rRNA Removal Kit. RNA-seq libraries were prepared with the NEBNext Ultra Directional RNA Library Prep Kit for Illumina (NEB) and sequenced at 1 3 75 bp on an Illumina NextSeq 500. The sequencing reads were assessed for data quality with FastQC v.0.11.3. The RNA-seq reads were then mapped to the human transcriptome (''GRCh38.primary.assembly.genome.fa and annotation.gtf'' files from GENCODE release 23) with RNA STAR v.2.4.0k. 12 The expression levels of the transcripts were quantified with rsem-1.2.22. 13 The resulting FPKM (fragments per kilobase of transcript per million mapped reads) values were transferred to Partek Genomics Suite 6.6 package. Principal-component analysis was performed with all FPKM values for the experiment and control samples for assessment of the variability between the replicates. Differentially expressed genes between the CUPID1 and CUPID2 siRNA experiments and controls were then identified by ANOVA (p < 0.05). The significance of overlap between CUPID1-and CUPID2-regulated genes was tested by hypergeometric distribution carried out by the R ''phyper'' function. Ingenuity Pathway Analysis (IPA) on the differentially expressed genes was conducted as described previously. 14 
Expression of CUPID1 and CUPID2 in TCGA Cohort
RNA-seq data from The Cancer Genome Atlas (TCGA) breast invasive carcinoma cohort (1,226 samples) were obtained from the UCSC Cancer Genomics Hub (September 30, 2015) . The procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national), and proper informed consent was obtained. Reads were trimmed for adaptor sequences with Cutadapt (v.1.11) and aligned with STAR (v.2.5.2a) to the GRCH37 assembly; the gene, transcript, and exon features of CUPID1 and CUPID2 were appended to the Ensembl (release 75) gene model. Quality-control metrics were computed with RNA-SeQC (v.1.1.8), and expression was estimated with RSEM (v.1.2.30).
Analysis of TCGA WGS Data
Whole-genome sequencing (WGS) data for 118 tumor and matched normal breast samples were accessed from TCGA data portal (Table S3 ). All TCGA data underwent reanalysis for standardization of the results used in the downstream analyses across all samples. Initially, fastq files were recreated from the BAM files. Sequence reads were then trimmed with Cutadapt (v.1.9) before alignment to GRCh37 with BWA-MEM (v.0.7.13-r1126). 15 Duplicate aligned reads were marked with Picard (v.1.141), and aligned data were sorted by coordinates with SAMtools (v.1.3). Somatic substitutions were detected by a dual calling strategy, and substitutions were detected with qSNP 16 and the HaplotypeCaller module of the Genome Analysis Toolkit. 17 High-confidence somatic substitutions used in downstream analysis passed variant-characteristic filtering: (1) minimum coverage depth of 8 reads for control data and 12 reads for tumor data; (2) at least 5 variant-supporting reads with individual start positions and for which the variant was not within the first or last 5 bases, was supported by reads in both sequencing directions, and was more than 5 bp from a mononucleotide run of 7 or more bases in length; and (3) somatic variants had <3% variant evidence identified in the control sample.
Defects in homologous recombination (HR) were assessed on the basis of the presence of mutational signatures and the distribution pattern of structural rearrangements. The flanking nucleotide context of high-confidence whole-genome somatic substitutions was used for generating mutational signatures for each sample according to a published framework. 18 Identified signatures were compared with other validated signatures (i.e., COSMIC), and the frequency of each signature per megabase was determined. Somatic structural variants (SVs) were identified with the qsv tool, and for genomes with >200 SV events, distinct patterns or clusters of breakpoint distributions were determined as described previously. [19] [20] [21] For the characterization of genomic breakpoint distributions, chromosomes bearing a significantly clustered distribution of breakpoints (as described in Korbel and Campbell 22 ; goodness-of-fit threshold p < 0.00001) and those containing outlying high numbers of rearrangement events were identified (outliers had a breakpoint-per-megabase rate exceeding 5 times the length of the inter-quartile range from the 75 th percentile for each sample with a minimum threshold of 30 breakpoints per chromosome). Genomes with fewer than 8 chromosomes with significantly clustered breakpoints and at least 1 containing an extreme outlying density of breakpoints were classified as containing focal rearrangement events. Genomes with 8 or more chromosomes with clustered breakpoints and a maximum of 1 extreme density event were classified as scattered. Manual review of breakpoint distribution confirmed the classifications and characterized borderline cases.
H2AX-FACS Method
Flow-cytometric assays using biotinylated anti-gH2AX (JBW301, Millipore) and DNA content staining with 7AAD (Invitrogen) were carried out as described previously, 23 and samples were acquired and analyzed with FACSCanto II (Becton Dickinson).
Immunofluorescence
Cells were seeded on coverslips and exposed to 5 Gy of ionizingradiation (IR) in a Gammacell. Cells were harvested after IR at different time points and pre-extracted with 0.5% NP-40 in cytoskeletal buffer (100 mM NaCl, 300 mM sucrose, 3 mM MgCl 2 , and 10 mM PIPES [pH 6.8]). Immunostaining for anti-RAD51 (sc-8349, Santa Cruz), anti-phospo-RPA (S4S8, Bethyl), anti-gH2AX (JBW301, Millipore), and anti-53BP1 (4937s, Cell Signaling) was performed as described previously. 24 
HR Assay
The MCF7 DR-GFP cell line was a gift from Dr. Maria Jasin and contains the DR-GFP cassette in MCF7 cells. The HR assay was performed as described previously. 25 
NHEJ Assay
The non-homologous end joining (NHEJ) reporter substrate has been described previously. 26 
Results lncRNAs Expressed from the 11q13 Breast Cancer Risk Locus
To identify lncRNAs transcribed from the 11q13 breast cancer risk locus, we performed RNA CaptureSeq on breast cancer cell lines by using capture probes designed to tile across a 390 kb intergenic region on 11q13 flanked by MYEOV and CCND1 (Table S2 ). We identified two lncRNAs that share a bidirectional promoter and are transcribed $20 kb away from PRE1, and we named these CUPID1 (transcribed from the positive strand) and CUPID2 (transcribed from the negative strand) ( Figures 1A, 1B , and S2). Multiple splice isoforms were detected for CUPID1, one of which corresponds to the RefSeq lncRNA gene LINC01488. A predicted lncRNA transcript corresponding to CUPID2 (AP000439.3) was also found in GENCODE (v.19; Figures 1A and 1B ).
Effect of Risk SNPs on the CUPID1 and CUPID2 Promoter PRE1 is a distal transcriptional enhancer within the 11q13 breast cancer risk region, and we have previously shown that it regulates the expression of CCND1. 4 Using 3C, we (B) Intron-exon structures of CUPID1 and CUPID2 transcripts identified by RNA CaptureSeq in MCF7 cells with or without estrogen stimulation. RefSeq lncRNA gene LINC01488 (CUPID1) and predicted lncRNA AP000439.3 (CUPID2) are shown in green, and CUPID1 and CUPID2 transcripts verified by PCR in MCF7 cells are indicated by red arrows ( Figure S2 ). The bottom panel shows chromatin immunoprecipitation sequencing data from ENCODE for DNaseI hypersensitivity (indicative of open chromatin), transcription factor binding sites (TFBSs), and chromatin state (ChromHMM). (C) 3C interaction profiles between PRE1 and the CUPID1 and CUPID2 bidirectional promoter in MCF7 and CAL51 cells. 3C libraries were generated with NcoI and an anchor point set at PRE1. A physical map of the region interrogated by 3C is shown above; gray shading represents the position of the CUPID1 and CUPID2 promoter. Error bars represent SD (n ¼ 3). (D) Luciferase reporter assays after transient transfection of MCF7 cells. PRE1 (PRE) was cloned downstream of a CUPID1-promoterdriven (Pr) luciferase (Luc) construct with and without the 11q13 risk-associated SNPs (rs ID). Error bars represent 95% confidence intervals (n ¼ 3). p values were determined by two-way ANOVA followed by Dunnett's multiple-comparison test (**p < 0.01, ***p < 0.001). (E) 3C followed by sequencing of PRE1 in heterozygous CAL51 breast cancer cells. Chromatograms represent one of two independent 3C libraries generated and sequenced. (F) PRE1 was epigenetically silenced in MCF7 cells with two different sgRNAs (SgPRE1 and SgPRE2). SgCON contains a non-targeting control guide RNA. Gene expression was measured by qPCR and normalized to TBP (MIM: 600075) and GUSB (MIM: 611499). Error bars represent the SEM (n ¼ 3). p values were determined by two-way ANOVA followed by Dunnett's multiple-comparison test (**p < 0.01, ***p < 0.001). (E) CUPID1 and CUPID2 expression in TCGA breast tumors stratified by the PAM50 intrinsic molecular subtypes (n ¼ 812). p values were determined by one-way ANOVA of the boxplots with Tukey outlier test (***p < 0.001, ****p < 0.0001). (F) Overlap of deregulated genes (p < 0.05) after siRNA-mediated silencing of CUPID1 or CUPID2 in MCF7 cells (Table S5 ). (G) 91/362 CUPID-regulated genes showed significant correlation with expression in TCGA breast tumors (n ¼ 812), consistent with the direction observed by CUPID1 and CUPID2 silencing (Table S9 ). Heatmaps show the average expression of each of the 91 genes in tumor showed that PRE1 also frequently interacted with the predicted CUPID1 and CUPID2 promoter in normal breast and cancer cell lines ( Figures 1C and S3 ). We also observed an additional interaction of unknown significance $5 kb from the CUPID1 and CUPID2 promoter. Reporter assays indicated that PRE1 acts as a strong enhancer on the CUPID1 and CUPID2 promoter, and inclusion of the minor (risk) allele of two of the four 11q13 breast cancer risk SNPs (rs661204 and rs78540526) significantly reduced the PRE1 enhancer activity only on the CUPID1 promoter ( Figures  1D, S4A, and S4B ). Furthermore, in CAL51 cells, a breast cancer cell line heterozygous for the risk SNPs, allele-specific 3C showed that only the protective allele participated in chromatin looping, suggesting that the risk allele abrogates looping between PRE1 and the CUPID1 and CUPID2 promoter ( Figures 1E and S4C ). We also silenced PRE1 by targeting a nuclease-inactive dCas9 fused to the Krüppelassociated box (KRAB) repressor (dCas9-KRAB) 27 to the PRE1 enhancer and confirmed that CUPID1, CUPID2, and CCND1 levels were significantly reduced ( Figure 1F ).
CUPID1 and CUPID2 Expression
RNA CaptureSeq data showed that CUPID2 was widely expressed in multiple tissues; however, CUPID1 was predominantly expressed in ER þ breast cancer cell lines ( Figure S5 ). Using qPCR in breast cell lines, we showed that CUPID1 and CUPID2 transcripts were more highly expressed in ER þ breast cancer cell lines. Higher expression was observed in BT474 and MCF7 cells, which were amplified at the 11q13 region (Figure 2A) . We determined the subcellular localization of CUPID1 and CUPID2 in relation to a number of well-characterized controls. As shown in Figure 2B , CUPID1 was enriched in the nucleus, whereas CUPID2 was nuclear and cytoplasmic. CUPID1 and CUPID2 expression was significantly induced in MCF7 cells treated with estrogen ( Figure 2C ). Notably, estrogen induction of the CUPID1 and CUPID2 promoter depended on the presence of PRE1; however, inclusion of the risk-associated SNPs did not attenuate this effect ( Figure S6 ). We also examined the expression of CUPID1 and CUPID2 in human breast tumors by using TCGA RNA-seq data. CUPID1 and CUPID2 were expressed in 60.1% and 78.7% of all breast tumors (FPKM R 0.1), respectively. Their expression was only weakly associated with 11q13 amplification, indicating that copy-number variation is not the sole mechanism underlying the observed overexpression ( Figure S7 ). CUPID1 and CUPID2 expression were highly correlated with each other (correlation ¼ 0.796), and similar to CCND1, both CUPID1 and CUPID2 were more highly expressed in HR þ tumors, specifically in luminal A and B subtypes ( Figures 2D, 2E , and S8).
Effect of CUPID1 and CUPID2 on Gene Expression
To gain insight into the potential functions of CUPID1 and CUPID2, we silenced both lncRNAs by using independent siRNAs in MCF7 cells and performed cell-cycle analyses ( Figure S9) . In contrast to CCND1 knockdown, CUPID1 and CUPID2 siRNA did not significantly alter cell-cycle progression ( Figure S10 ). Of note, CUPID1 and CUPID2 most likely regulate each other, as shown by reduced expression of both lncRNAs after either CUPID1 or CUPID2 siRNA treatment. We then performed RNA-seq and identified 1,847 and 1,835 genes that were differentially regulated between cells with repressed CUPID1 and CUPID2, respectively, and cells treated with a non-targeted control siRNA ( Figure 2F and Table S4 ). Notably, we observed a significant overlap (362 genes, p < 1eÀ100) of the genes regulated by both CUPID1 and CUPID2 ( Figure 2F and Table S5 ). Consistent with this, IPA of the CUPID1-and CUPID2-regulated genes showed an overlap in biological functions ( Figure S11A and Table S6 ), the majority of which are commonly disrupted in cancer. IPA of the overlapping genes identified five networks, of which the top networks were Molecular Transport, Cellular Assembly and Organization, and DNA Replication, Recombination, and Repair ( Figure S11B and Tables S7 and S8). Of the 362 genes regulated by both CUPID1 and CUPID2 and identified by silencing, approximately one-quarter (91/362 [25.1%]) correlated with CUPID1 and CUPID2 expression in the TCGA cohort ( Figure 2G and Table S9 ). Notably, we showed that CUPID1-and CUPID2-induced genes shared a similar pattern of high expression in HR þ , luminal A, and luminal B breast cancer subtypes. Conversely, CUPID1and CUPID2-supressed genes were inversely correlated with CUPID1 and CUPID2 expression across the same breast cancer subtypes ( Figure 2G ). These data suggest that CUPID1 and CUPID2 drive the expression of these genes in breast tumors.
CUPID1 and CUPID2 Silencing Inhibits HR-Mediated DNA Repair
We have previously shown that the strongest risk-associated SNPs at 11q13 act to reduce CCND1 expression, which conflicts with its demonstrated oncogenic function. 4 However, cyclin D1 also plays a role in HR-mediated DNA repair (HRR), a function independent of its role in cell-cycle control. 28 Given this and the fact that pathway analyses indicated that CUPID1-and CUPID2-regulated genes affect DNA repair and recombination, we hypothesized that PRE1 might act as an enhancer of other genes in the HRR pathway, including CUPID1 and CUPID2. In support of this, breast tumors with low CUPID1, CUPID2, or . CUPID1 and CUPID2 Silencing Impairs HRR (A) Low CUPID1 and CUPID2 expression is associated with a HR mutation signature. TCGA tumors were ranked on the basis of BRCA signature mutations per megabase, and those with high and low mutation rates (MRs), defined as the top and bottom quartiles, respectively, were compared for CUPID1 and CUPID2 expression with a two-sided t test. (B) TCGA tumors were classified on the basis of the observed patterns of SV distribution (focal, scattered, and mixed). The focal and scattered groups were compared for CUPID1 and CUPID2 expression with a two-sided t test. (C, E, and F) MCF7 DR-GFP (C) or MCF7 (E and F) cells were transiently transfected with two independent siRNA constructs against CUPID1 (CUPID1A and CUPID1B) or CUPID2 (CUPID2A and CUPID2B) for 48 hr. siCON denotes a non-targeting siRNA control, and siRAD51 was used as a positive control. consistent with defective HRR (Figures 3A, S12 , and S13A and Table S3 ). The same signature has previously been shown to be associated with mutations in two other HRR genes, BRCA1 (MIM: 113705) and BRCA2 (MIM: 600185). 29 Consistent with impaired HRR, low CUPID1, CUPID2, or CCND1 expression was associated with a large number of structural variants distributed through the genome 19 (Figures 3B, S13B , S14, and S15).
We then used a stable MCF7 cell line with two non-functional GFP alleles (MCF7 DR-GFP), in which GFP was activated only after HRR, and showed less efficient HR repair upon CUPID1 and CUPID2 knockdown by two independent siRNAs (Figures 3C and S16A) . Consistent with this, depletion of CUPID1 and CUPID2 by targeting of dCAS9-KRAB to the CUPID1 and CUPID2 bidirectional promoter also impaired HRR (Figures 3D and S17) . Importantly, re-expression of CUPID1 and/or CUPID2 in these cells almost completely restored efficient HR repair ( Figures  3D and S18A) . We also noted that re-expression of CUPID2 restored CUPID1 levels ( Figure S18A ). We then reduced CUPID1 and CUPID2 levels by using either siRNA or dCas9-KRAB targeted to the CUPID1 and CUPID2 promoter and observed that recruitment of RAD51 to IR-induced sites of DNA damage was impaired ( Figures 3E-3G , S16B, S17, and S19). Again, re-expression of CUPID1 and/or CUPID2 in the CUPID1-and CUPID2-silenced cells restored the formation of RAD51 foci after IR treatment ( Figures 3G  and S18B ). There was no significant change in CCND1 expression after knockdown or re-expression of either CUPID1 or CUPID2 (Figure S18C ).
CUPID1 and CUPID2 Regulate NHEJ and HR Pathway Choice
End resection is a key step in the initiation of HRR and involves the generation of a single-stranded DNA (ssDNA) stretch. This ssDNA stretch is then rapidly coated by the phosphorylated version of replication protein A (RPA) at residues S4 and S8 (pRPA) until it is subsequently replaced by RAD51. Given that RAD51 recruitment was impaired in CUPID1-and CUPID2-silenced cells, we performed immunofluorescence assays to interrogate the formation of pRPA foci after irradiation ( Figure 4A) . In contrast to control cells, in which pRPA peaked at 2 hr, cells depleted of CUPID1 and CUPID2 had significantly lower pRPA at 2 hr, which persisted until 4 hr before resolution ( Figures  4A, 4C, and S20 ). In addition, whereas CUPID1-and CUPID2-silenced cells had similar levels of gH2AX (a marker of DSBs) 0.5 hr after irradiation, CUPID1-and CUPID2-depleted cells had significantly higher levels of gH2AX foci 2 hr after irradiation, suggesting a mild delay in DSB repair ( Figures 4B and 4C ). Despite this delay, gH2AX foci were fully resolved after 16 hr. Consistent with this, we observed an increase in 53BP1 foci 2 hr after irradiation ( Figures 4B-4D) , indicating that DSB repair by NHEJ could be compensating for reduced HRR efficiency. We also calculated the percentage of cells with more than five gH2AX or 53BP1 foci per cell ( Figure 4E) as an indicator of DSBs primed for NHEJ repair and marked by their colocalization. The inverse correlation of the lower number of pRPA foci ( Figure 4D ) than of 53BP1 or gH2AX foci ( Figure 4E ) at 2 hr indicates a preference for NHEJ for DSB repair. To confirm whether the DSBs formed could be repaired by NHEJ in this HRR-deficient context, we used a reporter assay for NHEJ whereby successful repair of NHEJ after DNA digestion would restore expression of GFP. We observed a mild increase in NHEJ repair in MCF7 cells transfected with either CUPID1 or CUPID2 siRNA, suggesting that NHEJ could compensate for the loss of HRR ( Figures 4F and S16C) . Finally, the lack of a noticeable difference in the delay of the cell-cycle progression between CUPID1-and CUPID2-silenced cells and control cells ( Figure 4G ) supports the notion that the DNA DSBs in these mutant cells were eventually repaired.
Discussion
A key challenge for post-GWAS analysis is interpreting the mechanisms of action of risk-associated SNPs, given that the majority lie in noncoding regions of the genome. Although it is clear that cis-regulatory variation is a common mechanism underlying many associations, the role of lncRNAs in influencing disease susceptibility is only now being realized. Recent studies have indicated that lncRNAs are transcribed from cancer risk loci and that these transcripts can play important roles in tumorigenesis. [30] [31] [32] Here, we used RNA-seq to identify two estrogenregulated lncRNAs (CUPID1 and CUPID2) that might contribute to the risk of developing breast cancer by modulating pathway choice of DSB repair.
Using 3C, reporter assays, and CRISPRi, we showed that PRE1 acts as an enhancer on the CUPID1 and CUPID2 (D and G) MCF7 DR-GFP (D) or MCF7 (G) cells were depleted of CUPID1 and CUPID2 by targeting of dCAS9-KRAB to the bidirectional promoter (CUPID1-and CUPID2-CRISPRi). CUPID1 and/or CUPID2 expression was re-established by cDNA transient transfection. PgRNA denotes a CRISPRi non-targeting control. (C and D) HR/DR-GRP reporter assay. For each condition, the percentage of GFP þ cells in the siCON or vector control was subtracted from the percentage of pCMV-3xNLS-transfected cells. The HR percentage was calculated as the percentage of GFP þ cells in pCMV-ISceI-3xNLS-transfected cells divided by the percentage of GFP þ cells in the corresponding cells transfected with GFP plasmid. Error bars represent SEM (n ¼ 3). p values were determined by one-way ANOVA followed by Dunnett's multiple-comparison test (**p < 0.001, ****p < 0.0001). (E-G) IR-induced formation of RAD51 foci. Cells were exposed to a single dose of 5Gy IR, and RAD51 þ cells were quantified as the number of nuclei with >5 foci (scale bar in E, 10 mm). Error bars represent SEM (n ¼ 3). p values were determined by one-way ANOVA followed by Dunnett's multiple-comparison test (*p < 0.05). bidirectional promoter. In addition, allele-specific 3C performed in a cell line heterozygous for the risk SNPs between PRE1 and the CUPID1 and CUPID2 promoter showed preferential looping of the protective alleles. These findings suggest that risk-associated SNPs might abrogate chromatin looping and thus result in reduced promoter activity and subsequent transcription. 33 In addition, the risk SNPs reduced PRE1 activity on the CUPID1 promoter. However, in the absence of chromatin looping between PRE1 and the CUPID1 and CUPID2 promoter, the significance of this observation is unclear. These data would clearly be strengthened by analysis of isogenic lines with and without incorporation of the risk alleles. However, because this region is amplified in ER þ cell lines, it has not been possible to generate such cell lines.
We showed that both lncRNAs were induced after estrogen stimulation. Interestingly, the estrogen induction of CUPID1 and CUPID2 required the presence of PRE1, given that estrogen stimulation of a construct containing the promoter alone had no effect. In reporter assays, the risk SNPs did not affect the estrogen induction of the CUPID1 and CUPID2 promoters. This was not unexpected given that the risk SNPs are not predicted to affect ER binding. However, in cells heterozygous for the risk SNPs, we would expect that estrogen induction of CUPID1 and CUPID2 would occur only on the protective allele because chromatin looping was abrogated in the presence of the risk allele. Unfortunately, we did not identify any ER þ cell lines that were heterozygous for the risk SNPs; therefore, we could not confirm this by allele-specific expression analyses.
We provide evidence that CUPID1 and CUPID2 are important for HRR. Silencing of CUPID1 and CUPID2 delayed the formation of phosphorylated RPA foci and inhibited RAD51 recruitment to DBSs after irradiation, suggesting that reduced CUPID1 and CUPID2 expression might lead to a defect in end resection, a critical step required for the initiation of the HRR pathway. Notably, CUPID1 and CUPID2 silencing did not lead to increased gH2AX foci, suggesting that CUPID1 and CUPID2 do not affect overall DSB repair but most likely affect pathway choice for DNA repair. Consistent with this, the recruitment of 53BP1 to DSBs was promoted, and NHEJ was still functional, whereas HRR was decreased. Importantly, these data are consistent with our observations in breast tumors, where low CUPID1 and CUPID2 expression was associated with a HR mutation signature and high levels of scattered structural variants.
We previously reported that the breast cancer risk SNPs at 11q13 act to reduce the expression of CCND1, whose protein product, cyclin D1, is required for G1-to-S-phase cell-cycle transition. Cyclin D1 is recruited to sites of DNA damage, and reduction of cyclin D1 impairs the recruitment of RAD51 to DSBs and impedes HR DNA repair. 28 Our study on the same locus that affects CUPID1 and CUPID2 expression has revealed that these lncRNAs play a similar role in DSB repair. As depicted in our proposed model ( Figure S21 ), the loss of CUPID1 and CUPID2 expression results in reduced DNA end resection and defects in pRPA and RAD51 recruitment, leading to reduced HR DNA repair, and favors 53BP1 recruitment and the choice of NHEJ as the DNA-repair pathway. The role of BRCA1 and 53BP1 and associated partners in the choice of DNA repair pathway is an area of ongoing research. 34 Our results implicate CUPID1 and CUPID2 in this field, and future work should determine whether the lncRNAs directly affect DNA end resection, the relationship be-tween 53BP1, RIF1, and PTIP and/or BRCA1 and CtIP at the DSB sites, and/or chromatin remodelling, particularly through histone modification around the DNA breaks. Alternatively, CUPID1 might be acting as an RNA scaffold for DNA-repair complexes similarly to LINP1, which has recently been shown to promote NHEJ by acting as a RNA scaffold for Ku70-Ku80 and DNA-PKcs. 35 In summary, we have shown that breast cancer risk variants at 11q13 might regulate two lncRNAs, in addition to CCND1, and provide evidence that reduced expression of the lncRNAs mediates risk by favoring a switch from HRR to NHEJ DSB repair. Importantly, these data are consistent with observations in breast tumors whereby a HR mutation signature is associated with increased structural variants presumably caused by DSB repair through error-prone pathways. This study highlights the importance of annotating all noncoding RNAs expressed from GWAS loci and further consolidates the premise that aberrant lncRNA expression contributes to the etiology of many human cancers. Given that the majority of noncoding RNAs have no assigned function, lncRNAs are likely to provide a wealth of opportunities for uncovering novel pathways that could potentially be targeted for cancer therapy.
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